Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) FCF Margin (2017 - 2026)

Akebia Therapeutics has reported FCF Margin over the past 9 years, most recently at 53.9% for Q4 2025.

  • Quarterly FCF Margin rose 6351.0% to 53.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 28.66% through Dec 2025, up 5407.0% year-over-year, with the annual reading at 28.66% for FY2025, 5407.0% up from the prior year.
  • FCF Margin was 53.9% for Q4 2025 at Akebia Therapeutics, up from 47.69% in the prior quarter.
  • Over five years, FCF Margin peaked at 69.39% in Q3 2022 and troughed at 135.37% in Q1 2021.
  • The 5-year median for FCF Margin is 20.51% (2024), against an average of 24.48%.
  • Year-over-year, FCF Margin tumbled -16057bps in 2021 and then surged 18481bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 41.3% in 2021, then plummeted by -337bps to 98.02% in 2022, then soared by 96bps to 4.11% in 2023, then plummeted by -134bps to 9.61% in 2024, then soared by 661bps to 53.9% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's FCF Margin are 53.9% (Q4 2025), 47.69% (Q3 2025), and 35.57% (Q2 2025).